In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Athelas SA

Division of MerLion Pharmaceuticals Pte. Ltd.
www.athelas.com

Latest From Athelas SA

Deals Shaping the Medical Industry (03/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Recent Financings of Private Companies (10/2006)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have recieved venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

Deals Shaping the Medical Industry (10/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Biotechs Battle Bacteria

The rise in bacterial resistance has prompted a plethora of creative approaches to developing antibiotics. These range from finding completely novel targets to harnessing the body's own immune system to fight bacteria. And although biotechs have had the anti-bacterials space to themselves for the last few years, as more programs reach proof of concept, some Big Pharma may be showing signs of renewed interest.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • MerLion Pharmaceuticals Pte. Ltd.
  • Senior Management
  • Jean-Pierre Paccaud, PhD, CEO
  • Contact Info
  • Athelas SA
    Phone: (41) 22 347 46 61
    15 rue Lombard
    Geneva, 1205
    Switzerland
UsernamePublicRestriction

Register